Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
731.33
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
83
84
Next >
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Today 7:00 EDT
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.
Via
InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
April 22, 2024
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1...
Via
Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
April 22, 2024
After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course.
Via
InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
April 22, 2024
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits.
Via
Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Via
MarketBeat
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
April 19, 2024
Via
Benzinga
Eli Lilly and Co's Options Frenzy: What You Need to Know
April 17, 2024
Via
Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
April 22, 2024
Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of...
Via
TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
April 22, 2024
Capturing Consumer Spending on Health Care with XLV
Via
News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
April 20, 2024
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Via
The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
April 20, 2024
Low risk and high-reward potential? These stocks could offer both.
Via
The Motley Fool
SPDR ETF Report For Friday, April 19
April 20, 2024
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, April 19.
Via
Talk Markets
Topics
ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
April 19, 2024
The Nasdaq and S&P 500 tumbled below their 50-day lines.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
April 19, 2024
Investors should not ignore these highly rated stocks to buy now because they deserve their reputation as the market heats up.
Via
InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
April 18, 2024
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025.
Via
Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
April 18, 2024
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.
Via
Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
April 18, 2024
Via
Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
April 18, 2024
Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.
Via
InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
April 18, 2024
These stocks have taken different paths to where they are today, but both have been exceptional investments.
Via
The Motley Fool
Top Research Reports For Eli Lilly, Linde & Caterpillar
April 17, 2024
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).
Via
Talk Markets
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
April 17, 2024
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
Via
The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
April 17, 2024
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea.
Via
Investor's Business Daily
Nasdaq 100 Forecast: QQQ Inches Higher Ahead Of Fed Speakers
April 17, 2024
US stocks are pointing to a higher start, with corporate updates in focus, after Federal Reserve chair Jerome Powell raised doubts over the Fed's ability to cut rates this year.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
April 17, 2024
Goundbreaking results in treating obstructive sleep apnea (OSA) with Eli Lilly's tirzepatide. See significant reductions in apnea-hypopnea index (AHI) and body weight, offering hope for OSA patients.
Via
Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
April 17, 2024
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
Via
InvestorPlace
Topics
ETFs
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.
Via
Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
April 16, 2024
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Via
InvestorPlace
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
April 16, 2024
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28.
Via
Talk Markets
BTIG Research Predicts Over 118% Rally for These 3 Stocks
April 15, 2024
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
83
84
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.